#United States #Rockville #REGENXBIO #RGX-121 #MPS II

REGENXBIO's RGX-121: A Major Step in Treating MPS II

In a pivotal development for those battling Mucopolysaccharidosis II (MPS II), commonly known as Hunter syndrome, REGENXBIO Inc. (NASDAQ: RGNX) has announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) for its investigational gene therapy, clemidsogene lanparvovec, or RGX-121. This extension extends the Prescription Drug User Fee Act (PDUFA) goal date from November 9, 2025, to February 8, 2026.

The delay stems from the company’s timely submission of comprehensive, long-term clinical data concerning all patients enrolled in the pivotal study, which includes 13 participants. These findings, showcasing positive results from a 12-month follow-up, affirm the existing biomarker and neurodevelopmental data that REGENXBIO had previously provided for the BLA. The results will soon be discussed in further detail at the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025.

Understanding MPS II and the Urgent Need for Treatment

MPS II is a rare, X-linked recessive disorder that significantly affects boys, causing a progressive decline in cognitive and physical capabilities due to a deficiency in the enzyme iduronate-2-sulfatase (IDS). The consequent accumulation of glycosaminoglycans (GAGs) in various tissues leads to debilitating health challenges. As the disease progresses, symptoms typically become evident by the age of 2, manifesting as developmental delay, difficulties in mobility, and neurological decline. Currently, there are no therapeutic options available that can effectively halt the neurodevelopmental deterioration associated with the disease, underlining an urgent need for an effective treatment.

RGX-121: Potential Breakthrough Therapy

RGX-121 represents a potential one-time treatment that aims to address the root genetic cause of MPS II. By delivering the IDS gene to the central nervous system (CNS), RGX-121 aims to restore the deficient enzyme function beyond the blood-brain barrier—an area that conventional treatments struggle to reach. This therapy holds the promise of providing a lasting correction of cellular function throughout the CNS, crucial for managing the neurological symptoms of this severe disease. The current version of the I2S protein produced by RGX-121 is structurally identical to the natural protein, enhancing the likelihood of successful treatment outcomes.

Regulatory Recognition of RGX-121

The regulatory framework surrounding RGX-121 is promising. The therapy has been granted multiple designations by the FDA, including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT). Additionally, the European Medicines Agency has classified it as an advanced therapy medicinal product (ATMP). These recognitions signify the treatment’s potential impact on the quality of life for those diagnosed with MPS II, as well as the speed at which it may move through the regulatory process.

Future Outlook for REGENXBIO

Looking ahead, REGENXBIO’s CEO Curran M. Simpson emphasized the urgency of delivering a therapeutic option for the Hunter syndrome community, which currently lacks adequate treatment alternatives. With the comprehensive data submitted to the FDA and positive results indicating RGX-121's efficacy, the company is optimistic about aligning its commercialization plans with the extended review timeline.

In September, during the ICIEM, further pivotal data are expected to surface, reinforcing the potential of RGX-121 in the treatment spectrum for MPS II. With continued advancements in gene therapy, particularly through REGENXBIO’s innovation, there lies hope for improved solutions for rare conditions that affect countless young lives worldwide.

Conclusion

As REGENXBIO prepares for the extended FDA review and the upcoming presentation at ICIEM, the biotech company stands at the forefront of translating scientific innovation into real-world therapies. The journey of RGX-121 captures not only the complexities of rare diseases but also the relentless pursuit of solutions that can change lives. In a landscape where hope often feels scarce, REGENXBIO represents a beacon for those grappling with the challenges of Hunter syndrome.